Skip to main content
Journal cover image

The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.

Publication ,  Journal Article
Younossi, Z; Stepanova, M; Sanyal, AJ; Harrison, SA; Ratziu, V; Abdelmalek, MF; Diehl, AM; Caldwell, S; Shiffman, ML; Schall, RA; McColgan, B ...
Published in: J Hepatol
December 2018

BACKGROUND & AIMS: Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis and NASH-related cirrhosis from a cohort with longitudinal follow-up data. METHODS: Patients with cryptogenic cirrhosis or NASH cirrhosis were screened for a clinical trial. Patients with <5% hepatic steatosis regardless of other histologic features were considered to have cryptogenic cirrhosis. Clinico-laboratory data and adjudicated liver-related events (e.g. decompensation, qualification for transplantation, death) were available. RESULTS: A total of 247 patients with cirrhosis (55.3 ± 7.4 years, 37% male) were included; 144 had NASH cirrhosis and 103 had cryptogenic cirrhosis. During a median follow-up of 29 (IQR 21-33) months (max 45 months), 20.6% of patients had liver-related clinical events. Patients with NASH cirrhosis and cryptogenic cirrhosis were of a similar age and gender, as well as having a similar body mass index, PNPLA3 rs738409 genotype, and prevalence of diabetes (p >0.05). However, patients with cryptogenic cirrhosis had higher serum fibrosis markers and greater collagen content and α-smooth muscle actin expression on liver biopsy. Compared to cirrhotic patients with NASH, patients with cryptogenic cirrhosis experienced significantly shorter mean time to liver-related clinical events (12.0 vs. 19.4 months; p = 0.001) with a hazard ratio of 1.76 (95% CI 1.02-3.06). CONCLUSIONS: Populations with NASH and cryptogenic cirrhosis have similar demographics, but patients with cryptogenic cirrhosis have evidence of more active fibrosis and a higher risk of liver-related clinical events. Thus, we believe these patients belong to the same spectrum of disease, with cryptogenic cirrhosis representing a more advanced stage of fibrosis. LAY SUMMARY: Significant liver damage and cirrhosis of the liver may develop without a known cause - a liver disease referred to as cryptogenic cirrhosis. In this work we found that, in the presence of metabolic abnormalities, cryptogenic cirrhosis may actually be a part of the non-alcoholic fatty liver disease spectrum. Yet, it appears to be more progressive than typical non-alcoholic fatty liver disease, leading to advanced liver disease at a faster rate.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Hepatol

DOI

EISSN

1600-0641

Publication Date

December 2018

Volume

69

Issue

6

Start / End Page

1365 / 1370

Location

Netherlands

Related Subject Headings

  • Prospective Studies
  • Prevalence
  • Outcome Assessment, Health Care
  • Non-alcoholic Fatty Liver Disease
  • Middle Aged
  • Metabolic Syndrome
  • Male
  • Longitudinal Studies
  • Liver Cirrhosis
  • Liver
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Younossi, Z., Stepanova, M., Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., … Goodman, Z. (2018). The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. J Hepatol, 69(6), 1365–1370. https://doi.org/10.1016/j.jhep.2018.08.013
Younossi, Zobair, Maria Stepanova, Arun J. Sanyal, Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, et al. “The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.J Hepatol 69, no. 6 (December 2018): 1365–70. https://doi.org/10.1016/j.jhep.2018.08.013.
Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, et al. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. J Hepatol. 2018 Dec;69(6):1365–70.
Younossi, Zobair, et al. “The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.J Hepatol, vol. 69, no. 6, Dec. 2018, pp. 1365–70. Pubmed, doi:10.1016/j.jhep.2018.08.013.
Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Schall RA, McColgan B, Subramanian GM, Myers RP, Muir A, Afdhal NH, Bosch J, Goodman Z. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. J Hepatol. 2018 Dec;69(6):1365–1370.
Journal cover image

Published In

J Hepatol

DOI

EISSN

1600-0641

Publication Date

December 2018

Volume

69

Issue

6

Start / End Page

1365 / 1370

Location

Netherlands

Related Subject Headings

  • Prospective Studies
  • Prevalence
  • Outcome Assessment, Health Care
  • Non-alcoholic Fatty Liver Disease
  • Middle Aged
  • Metabolic Syndrome
  • Male
  • Longitudinal Studies
  • Liver Cirrhosis
  • Liver